KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $258.6 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) fell 91.95% to $258.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.6 million, marking a year-over-year decrease of 91.95%. This contributed to the annual value of $257.9 million for FY2024, which is 99.81% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $258.6 million for Q3 2025, which was down 91.95% from $259.2 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $261.9 million during Q1 2021, and its lowest value of $257.9 million during Q1 2022.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $259.8 million, with a median of $259.9 million in 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) plummeted by 152.73% in 2022 and then soared by 93.06% in 2023.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $259.9 million in 2021, then dropped by 0.31% to $259.1 million in 2022, then grew by 0.54% to $260.5 million in 2023, then decreased by 1.0% to $257.9 million in 2024, then increased by 0.27% to $258.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $258.6 million for Q3 2025, versus $259.2 million for Q2 2025 and $259.5 million for Q1 2025.